Skip to content
Screener

United Therapeutics UTHR Q3 2025 earnings

Reported October 29, 2025 · Before market open

Revenue$799.5MMiss by $15.3M
EPS$7.16Beat by $0.27
Revenue estimate$814.8M
EPS estimate$6.89

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$789.5M
EPS estimate$6.44

Financials

Q3 2025

Income statement

See full
Revenue$799.5M+6.8%
Gross profit$698.6M+4.9%
Operating income$388.5M+13.2%
Net income$338.7M+9.6%
EPS (diluted)$7.16+12.1%

Balance sheet

See full
Cash & equivalents$1.3B-13.8%
Total equity$6.6B+8.0%
Total assets$7.4B+3.2%

Cash flow

See full
Operating cash flow$562.1M+49.0%
CapEx$210.5M+175%
Free cash flow$351.6M+16.9%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$18.96B+19.2%
P/E14.9×+0.6×
P/S6.1×+0.3×

Profitability

See full
Gross margin88.6%-0.3pp
Operating margin47.7%+1.3pp
Net margin40.7%+0.3pp
FCF margin35.9%+3.3pp

Returns & leverage

See full
Return on equity20%+1.2pp
Current ratio6.4×+1.8×

Segments

By product

See full
Tyvaso DPI$336.2M+22.4%
Nebulized Tyvaso$141.8M-10.9%
Orenitram$131.1M+15.8%
Remodulin$125.9M-1.9%
Unituxin$47.9M-21.6%

FAQ

When did United Therapeutics report Q3 2025 earnings?
United Therapeutics (UTHR) reported Q3 2025 earnings on October 29, 2025 before market open.
What were United Therapeutics's Q3 2025 revenue and EPS?
United Therapeutics reported revenue of $799.5M and eps of $7.16 for Q3 2025.
Did United Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $814.8M by $15.3M. EPS beat the consensus estimate of $6.89 by $0.27.
How did United Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 6.8% from $748.9M a year earlier and eps grew 12.1% from $6.39.
Where can I find United Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001082554-25-000036) and the 10-Q periodic report (0001082554-25-000034) directly on SEC EDGAR. The filing index links above go to sec.gov.